The prognosis of advanced soft-tissue sarcomas (STS) and metastatic or high-risk localized small round cell tumor (SRCT) is dismal with a low proportion of patients surviving free of disease after conventional chemotherapy.
1,2 Thus, novel approaches for the treatment of advanced sarcomas are needed.
From November 1999 to December 2002, nine patients with advanced sarcoma having an HLA-identical sibling were treated with a reduced-intensity conditioning regimen followed by allogeneic peripheral stem cell transplantation. Patients were treated with two reduced conditioning regimens: fludarabine 125 mg/m 2 for 5 days plus cyclophosphamide 120 mg/kg for 2 days (FluCy1), and fludarabine 90 mg/m 2 plus cyclophosphamide 900 mg/m 2 for 3 days (FluCy2), based on clinical status at transplantation. One patient received melphalan 140 mg/m 2 instead of cyclophosphamide on account of previous treatment.
GvHD prophylaxis consisted of continuous infusion of cyclosporine (CsA) alone from day À1 (3 mg/kg/day) in seven patients, supplemented by a short course of methotrexate (day þ 1 ¼ 15 mg/m 2 ; days þ 3, þ 6, þ 11 ¼ 10 mg/m 2 ) in two patients. HLA-identical siblings were mobilized by means of subcutaneous glycosylated rhu-G-CSF 10 mg/kg/day every 12 h from day À4 to leukapheresis. The target stem-cell dose was fixed at 4 Â 10 6 CD34 þ /kg of recipient. Stem cells were freshly reinfused without any manipulations.
Chimerism was assessed by means of standard cytogenetic or FISH procedures in sex-mismatched pairs, or informative PCR sequences in sex-matched pairs.
Patient characteristics are reported in Table 1 . Seven patients (77%) received high-dose chemotherapy followed by autologous stem cell reinfusion (HDCT) to obtain maximal tumor regression before allogeneic transplantation. The median time elapsed from HDCT to allogeneic transplant was 80 days (range 60-150).
Clinical results are reported in Table 2 . Overall, after a median follow-up of 23 months from allogeneic transplant, progressive disease (PD) was observed in seven patients (77%), in one patient disease was stable, and one patient was not evaluable because of early toxic death. At last follow-up, four patients were alive with disease. The median overall survival was 367 days (range 12-665). Six out of eight evaluable patients (75%) developed clinical signs of aGvHD grade II/B or III/C. Steroid treatment (2 mg/kg/day) was effective in all patients. Extensive cGvHD, analyzed before and after immunomodulation, was observed in four (57%) out of seven evaluable patients and treated with an alternate scheme or CsA plus mycophenolate mofetil. Chimerism was analyzed in unseparated peripheral blood. At day þ 90, all but one patient was full donor.
No severe mucosal, renal, hepatic, or pulmonary toxicity was observed. Bacterial infections were reported in two patients: one died of septic shock due to pseudomonas aeruginosa (day þ 12) and one patient developed a possible lung fungal infection. Three patients reactivated CMV, detected by antigenemia pp65; however, no CMV-related disease occurred. Treatment-related mortality (TRM) was 22% (2/9) due to septic shock in one case, and cGvHD in the other.
Eight patients who progressed underwent additional immunomodulatory treatment. In a two-step process, CsA withdrawal was firstly considered in these patients. After this first step, four patients were in PD, three patients were stable, and one was not evaluable because he committed suicide. Overall, aGvHD was observed in one patient, and extensive cGvHD in two. The second step consisted of DLI in progressive or stable patients with no clinical signs of GvHD. Four patients received DLI. The median number of reinfusions was 1 (range 1-3), and the median number of CD3 þ cells per kilo reinfused was 8 Â 10 7 /kg (range 0.1-9). The median time from progression to DLI was 60 days (range 30-180). All four patients progressed. One patient developed GvHD which was clinically chronic.
Over the last few years, there has been increasing experimental and clinical evidence showing that allogeneic stem-cell transplantation, initially developed for the treatment of hematological malignancies, has a mechanism of action closely related to an immune-mediated graft-versustumor (GvT) effect. In order to reduce the toxicity and simultaneously exploit the GvT potential, several reducedintensity conditioning regimens have been developed. The possibility of establishing a GvT effect against nonhematological malignancies is of great interest. Regression of metastatic renal cancer was been previously reported. 3 However, no clear evidence exists concerning the therapeutic activity of such an approach in other solid tumors. For many reasons, such as chemoresistance, young age at diagnosis, and absence of a dose-response effect, advanced sarcomas appeared to be a good choice for testing the efficacy of this 'new' therapeutic strategy. Furthermore, some subtypes of sarcoma express specific genetic abnormalities which could be exploited for immunotherapy as suggested by Worley et al. 4 Thus, in this series, patients with poor prognosis SRCT and STS were included.
Our data suggest that soft-tissue sarcomas are not susceptible to immune attack because progression was observed in the majority of patients. This is also confirmed by the results obtained with a modulation of immune response to elicit stronger lymphocyte activation in progressing patients. Neither CsA withdrawal nor DLI were followed by durable response, even in the presence of GvHD. These results are similar to results previously reported. 5 More recently, 11 advanced-sarcoma patients were treated with RIC (fludarabine, busulfan, and rabbit antithymocyte globulin) followed by peripheral-blood stem cell transplantation obtaining two durable CR. 6 Overall, the TRM was acceptable (22%).
Our data suggest that allogeneic transplantation should not be considered active against STS. 
